Craft

Shanghai Junshi Biosciences

Stock Price

$13.8

2024-10-29

Market Capitalization

$27 B

2024-10-29

Revenue

¥2.4 B

FY, 2025

Shanghai Junshi Biosciences Summary

Company Summary

Overview
Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company dedicated to the discovery and development of drugs. Its platform technology of protein engineering enables the development of small molecule and macromolecular drugs as well as antibody drug conjugates for the treatment of cancer, autoimmune, and metabolic diseases. In addition, the company engages in the development of biologic drug candidates to treat tumors, psoriasis, multiple sclerosis, osteoporosis, migraine, etc.
Type
Public
Status
Active
Founded
2012
HQ
Shanghai, CN | view all locations
Website
http://junshipharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Feng Hui

    Feng Hui, Executive Director and Chief Operations Officer

    • Zhang Zhuobing

      Zhang Zhuobing, Executive Director, Deputy General Manager

      • Yao Sheng

        Yao Sheng, Executive Director, Deputy Generalmanager and Senior Vice President

        • Li Ning

          Li Ning, Executive Director, chief executive officer and general manager

          LocationsView all

          1 location detected

          • Shanghai, Shang Hai Shi HQ

            China

            15F, Building 7, No.6, Lane 100, Pingjiaqiao Road

          Shanghai Junshi Biosciences Financials

          Summary Financials

          Revenue (Q1, 2026)
          ¥720.2M
          Gross profit (Q1, 2026)
          ¥573.2M
          Net income (Q1, 2026)
          (¥43.4M)
          Cash (Q1, 2026)
          ¥3.9B
          EBIT (Q1, 2026)
          (¥122.9M)
          Enterprise value
          $29.1B

          Footer menu